You are here

Article Text

Article menu
Download PDFPDF
PostScript
Correspondence
The Authors' reply
  1. Steve W Goodacre1,
  2. Paul Collinson2,
  3. Alasdair Gray3,
  4. on behalf of the RATPAC Research Team
  1. 1School of Health and Related Research, University of Sheffield, Sheffield, UK
  2. 2Departments of Clinical Blood Sciences and Cardiology, St George's Hospital, London, UK
  3. 3Accident & Emergency Department, Royal Infirmary of Edinburgh, Edinburgh, UK
  1. Correspondence to Professor Steve W Goodacre, School of Health and Related Research, University of Sheffield, Regent Court, 30 Regent Street, Sheffield S1 4DA, UK; s.goodacre{at}sheffield.ac.uk

https://doi.org/10.1136/heartjnl-2011-301343

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The Authors' reply The Randomised Assessment of Treatment using Panel Assay of Cardiac Markers (RATPAC) trial was a pragmatic evaluation comparing a specific point-of-care panel assessment to what is still standard diagnostic assessment for suspected myocardial infarction, a 12-hour laboratory troponin. The studies by Keller et al1 and Reichlin et al2 show that modern high sensitivity troponin assays have better sensitivity than older assays but troponin measurement at presentation is still suboptimal compared with delayed measurement. We are currently undertaking an economic analysis to determine whether delayed troponin measurement is cost effective compared with measurement at presentation.3 Until this analysis is undertaken, delayed troponin …

    View Full Text

    Footnotes

    • Linked article 301342.

    • Competing interests None.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles